Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.

888 indexed citations

Abstract

loading...

About

This paper, published in 1999, received 888 indexed citations. Written by Shin Onizuka, Isao Tawara, Jun Shimizu, Shimon Sakaguchi, Takashi Fujita and Eiichi Nakayama covering the research area of Immunology. It is primarily cited by scholars working on Immunology (809 citations), Oncology (393 citations) and Molecular Biology (84 citations). Published in PubMed.

In The Last Decade

doi.org/w75668849 →

Countries where authors are citing Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.

Specialization
Citations

This map shows the geographic impact of Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. more than expected).

Fields of papers citing Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.

Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody..

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

This paper is also available at doi.org/w75668849.

Explore hit-papers with similar magnitude of impact

Rankless by CCL
2026